Company Encyclopedia
View More
name
maccura
300463.SZ
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems and semi-automatic urine analyzers; and hemostasis solutions, including coagulation and semi-automatic coagulation analyzers. It provides clinical chemistry products, such as glycohemoglobin and protein analyzer, biochemistry systems, and chemistry regents; blood group product solutions; and pathology solutions, such as a liquid-based cytology processing system. Maccura Biotechnology Co.Ltd was founded in 1994 and is headquartered in Chengdu, China.
561.60 B
300463.SZMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking24/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.83%D
    • Profit Margin-5.32%D
    • Gross Margin55.65%B
  • Growth ScoreE
    • Revenue YoY-19.03%E
    • Net Profit YoY-136.11%E
    • Total Assets YoY-2.64%D
    • Net Assets YoY-3.61%D
  • Cash ScoreE
    • Cash Flow Margin-1880.60%E
    • OCF YoY-19.03%E
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreA
    • Gearing Ratio20.15%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Maccura released its performance for the first three quarters, with a net profit attributable to the parent company of 37.1034 million yuan, a decrease of 86.81%

    Maccura released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 1.608 billion yuan, a year-on-year decrease of 17.44%. The net profit attributable to the parent company was 37.1034 million yuan, a year-on-year decline of 86.81%; the net profit after deducting non-recurring gains and losses was 64.3071 million yuan, a year-on-year decrease of 77.95%. The basic earnings per share were 0.0606 yuan

    Zhitong·
    SZ
    300463
    +0.61%
    Zhitong·
    SZ
    300463
    +0.61%

    Maccura released its performance for the first half of the year, with a net profit attributable to the parent company of 34.0425 million yuan, a decrease of 83.12%

    Maccura released its 2025 semi-annual report, with operating revenue of 1.075 billion yuan, a year-on-year decrease of 15.94%. The net profit attributable to the parent company was 34.0425 million yuan, a year-on-year decline of 83.12%. The net profit after deducting non-recurring gains and losses was 63.0562 million yuan, a year-on-year decrease of 68.24%. The basic earnings per share were 0.0556 yuan. Revenue from self-developed products was 872 million yuan, a year-on-year decrease of 6.49%, accounting for 81.11% of operating revenue

    Zhitong·
    SZ
    300463
    +0.61%
    Zhitong·
    SZ
    300463
    +0.61%

    Maccura has obtained multiple medical device registration certificates

    According to the Zhitong Finance APP, Maccura announced that the company recently received the "Medical Device Registration Certificate" (in vitro diagnostic reagents) issued by the Sichuan Drug Administration. The product names are: Coagulation Factor V Activity Assay Kit (Coagulation Method), Coagulation Factor II Activity Assay Kit (Coagulation Method), Coagulation Factor X Activity Assay Kit (Coagulation Method), and Coagulation Factor VII Activity Assay Kit (Coagulation Method)

    Zhitong·
    SZ
    300463
    +0.61%
    Zhitong·
    SZ
    300463
    +0.61%

    Maccura pays supplementary taxes, expected to impact annual net profit attributable to shareholders by 21.2815 million yuan

    Maccura announced that due to the tax department's inspection of the tax situation from 2021 to 2023, the company needs to pay back taxes totaling 35.1245 million yuan, including corporate income tax, value-added tax, etc. The payment has been completed as required, and the competent tax authority has not imposed any penalties. It is expected to impact the net profit attributable to the parent company for the year 2025 by 21.2815 million yuan, subject to the final audited financial report

    Zhitong·
    SZ
    300463
    +0.61%
    Zhitong·
    SZ
    300463
    +0.61%

    Maccura shareholder Guo Lei and his concerted parties plan to reduce their holdings by no more than 2.68%

    Maccura's shareholder Guo Lei and his concerted actors plan to reduce their holdings by no more than 2.68% within 90 days after the announcement, totaling no more than 16.3279 million shares. The reduction will be conducted through centralized bidding and block trading, with a reduction window period of 15 trading days after the announcement during which no reduction will take place

    Zhitong·
    SZ
    300463
    +0.61%
    Zhitong·
    SZ
    300463
    +0.61%
    © 2025 Longbridge｜Disclaimer